Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ProPhase Labs, Inc.PRPH · Entity 8699 | Director · CEO & CHAIRMAN | September 09, 2025 | September 11, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ProPhase Labs, Inc.
Report date September 09, 2025 · Filed September 11, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| warrantsSEC Table II · derivative / convertible security · Conversion / exercise price $0.60 · Expires 2030-09-09 | Direct | 500,000 |
Reported balance
After 2025-09-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-09-09 · Grant · Acquired 500,000 · Balance 500,000 F1: Warrants issued upon increase in authorized shares being approved by shareholders. The Reporting Person loaned PRPH funds, with a contingency that a warrant to purchase 500,000 shares of the Issuer's common stock at an exercise price of $0.60 per share would be issued if and only if the company's shareholders approved an amendment to the Certificate of Incorporation increasing the authorized shares of common stock from 50,000,000 to 1,000,000,000. Shareholders approved the increase in the authorized shares on September 9, 2025. The Warrant is described in the Issuer's Current Report on Form 8-K/A filed June 26, 2025 (Item 1.01), which states the Warrant has a five-year term. The expiration date shown (09/09/2030) is a five-year term from the issuance date. The Warrant was issued as consideration in connection with a related-party loan agreement between the Issuer and the Reporting Person dated June 22, 2025. See Form 8-K/A filed June 26, 2025 for additional details. |
Filing footnotes · ownership attribution and instrument terms
F1: Warrants issued upon increase in authorized shares being approved by shareholders. The Reporting Person loaned PRPH funds, with a contingency that a warrant to purchase 500,000 shares of the Issuer's common stock at an exercise price of $0.60 per share would be issued if and only if the company's shareholders approved an amendment to the Certificate of Incorporation increasing the authorized shares of common stock from 50,000,000 to 1,000,000,000. Shareholders approved the increase in the authorized shares on September 9, 2025. The Warrant is described in the Issuer's Current Report on Form 8-K/A filed June 26, 2025 (Item 1.01), which states the Warrant has a five-year term. The expiration date shown (09/09/2030) is a five-year term from the issuance date. The Warrant was issued as consideration in connection with a related-party loan agreement between the Issuer and the Reporting Person dated June 22, 2025. See Form 8-K/A filed June 26, 2025 for additional details.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 09, 2025 Filed Sep 11, 2025 20:05 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | Grantwarrants · Derivative | 500,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001641172-25-027126 · ownership.xml · derivative · entry 1 Karkus Ted William · CIK 0001457896 · Director · CEO & CHAIRMAN 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2030-09-09 F1 · derivative.exercise_date: Warrants issued upon increase in authorized shares being approved by shareholders. The Reporting Person loaned PRPH funds, with a contingency that a warrant to purchase 500,000 shares of the Issuer's common stock at an exercise price of $0.60 per share would be issued if and only if the company's shareholders approved an amendment to the Certificate of Incorporation increasing the authorized shares of common stock from 50,000,000 to 1,000,000,000. Shareholders approved the increase in the authorized shares on September 9, 2025. The Warrant is described in the Issuer's Current Report on Form 8-K/A filed June 26, 2025 (Item 1.01), which states the Warrant has a five-year term. The expiration date shown (09/09/2030) is a five-year term from the issuance date. The Warrant was issued as consideration in connection with a related-party loan agreement between the Issuer and the Reporting Person dated June 22, 2025. See Form 8-K/A filed June 26, 2025 for additional details. Read SEC document |
| March 17, 2024 Filed Mar 20, 2024 01:48 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | GrantOption (right to buy) · Derivative | 400,000 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001493152-24-010570 · ownership.xml · derivative · entry 1 Karkus Ted William · CIK 0001457896 · Director · CEO & CHAIRMAN · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2031-03-17 F1 · derivative.exercise_date: Options shall vest and become exercisable in four equal installments, with 25% of such award vesting and becoming exercisable on the grant date and the remainder vesting and becoming exercisable in equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document |
| March 17, 2024 Filed Mar 21, 2024 20:30 UTC Amendment | ProPhase Labs, Inc. PRPH · Entity 8699 | GrantOption (right to buy) · Derivative | 400,000 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001493152-24-010787 · ownership.xml · derivative · entry 1 Karkus Ted William · CIK 0001457896 · Director · CEO & CHAIRMAN · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2031-03-17 F2 · shares: This amended report on Form 4 is being filed to correct the information in Table II, Box 5 as the share amount was inadvertently reported under the wrong subheading in the original Form 4 filed on March 19, 2024. F1 · derivative.exercise_date: Options shall vest and become exercisable in four equal installments, with 25% of such award vesting and becoming exercisable on the grant date and the remainder vesting and becoming exercisable in equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document |
| April 05, 2023 Filed Apr 5, 2023 20:38 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | GiftCommon Stock, par value $0.005 | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-011050 · ownership.xml · nonDerivative · entry 2 Karkus Ted William · CIK 0001457896 · Director · CEO & CHAIRMAN · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Son Disclosed balance after: 150,000 F1 · kind: This transaction involved a gift of securities by the Reporting Person to his son, who shares the Reporting Person's household. F2 · ownership.nature: Shares held by Reporting Person's son, who shares the Reporting Person's household. Read SEC document |
| April 05, 2023 Filed Apr 5, 2023 20:38 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | GiftCommon Stock, par value $0.005 | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-011050 · ownership.xml · nonDerivative · entry 1 Karkus Ted William · CIK 0001457896 · Director · CEO & CHAIRMAN · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,433,750 F1 · kind: This transaction involved a gift of securities by the Reporting Person to his son, who shares the Reporting Person's household. Read SEC document |
| April 03, 2023 Filed Apr 4, 2023 20:27 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | GrantOption (right to buy) · Derivative | 500,000 | $0.00 Strike: $9.00 | $0.00 |
DisclosureSEC source: 0001493152-23-010830 · ownership.xml · derivative · entry 3 Karkus Ted William · CIK 0001457896 · Director · CEO & CHAIRMAN · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2031-04-02 F3 · derivative.exercise_date: The transaction reported in this row involves a grant by the Issuer to the Reporting Person of options to purchase the Issuer's common stock that will vest in five equal annual installments beginning April 3, 2024, subject to the Reporting Person's continued employment with the Issuer on each vesting date. Read SEC document |
| April 03, 2023 Filed Apr 4, 2023 20:27 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | GiftCommon Stock, par value $0.005 | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-010830 · ownership.xml · nonDerivative · entry 1 Karkus Ted William · CIK 0001457896 · Director · CEO & CHAIRMAN · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,483,750 F1 · kind: This transaction involved a gift of securities by the Reporting Person to his son, who does not share the Reporting Person's household. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 21:33 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | Exercise / conversionOption (right to buy) · Derivative | 500,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001493152-23-003428 · ownership.xml · derivative · entry 4 Karkus Ted William · CIK 0001457896 · Director · CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 500,000 shares Expires 2023-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On February 1, 2023, the Reporting Person acquired net 231,663 shares of common stock upon the exercise of stock options to purchase 500,000 shares of common stock, less 268,337 shares of common stock withheld to cover the exercise price and applicable taxes. F2 · derivative.exercise_date: The option vested in 35 equal monthly installments of 63,888 shares on the 1st day of each month beginning on March 1, 2018 (the "Initial Vesting Date"), and one monthly installment of 63,920 shares on the 1st day of the 36th month following the Initial Vesting Date, as described in a stock option award agreement by and between the Issuer and the Reporting Person, dated as of February 19, 2018. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 21:33 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | Tax withholdingCommon Stock, par value $0.005 | 268,337 | $8.18 | $2,194,996.66 |
DisclosureSEC source: 0001493152-23-003428 · ownership.xml · nonDerivative · entry 2 Karkus Ted William · CIK 0001457896 · Director · CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,583,750 F1 · kind: On February 1, 2023, the Reporting Person acquired net 231,663 shares of common stock upon the exercise of stock options to purchase 500,000 shares of common stock, less 268,337 shares of common stock withheld to cover the exercise price and applicable taxes. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 21:33 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | Exercise / conversionCommon Stock, par value $0.005 | 500,000 | $0.60 | $300,000.00 |
DisclosureSEC source: 0001493152-23-003428 · ownership.xml · nonDerivative · entry 1 Karkus Ted William · CIK 0001457896 · Director · CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,852,087 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On February 1, 2023, the Reporting Person acquired net 231,663 shares of common stock upon the exercise of stock options to purchase 500,000 shares of common stock, less 268,337 shares of common stock withheld to cover the exercise price and applicable taxes. Read SEC document |
| January 13, 2023 Filed Jan 17, 2023 21:37 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | Exercise / conversionOption (right to buy) · Derivative | 600,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001493152-23-001631 · ownership.xml · derivative · entry 4 Karkus Ted William · CIK 0001457896 · Director · CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 600,000 shares Expires 2023-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On January 13, 2023, the Reporting Person acquired net 280,769 shares of common stock upon the exercise of stock options to purchase 600,000 shares of common stock, less 319,231 shares of common stock withheld to cover the exercise price and applicable taxes. F2 · derivative.exercise_date: The option vested in 35 equal monthly installments of 63,888 shares on the 1st day of each month beginning on March 1, 2018 (the "Initial Vesting Date"), and one monthly installment of 63,920 shares on the 1st day of the 36th month following the Initial Vesting Date, as described in a stock option award agreement by and between the Issuer and the Reporting Person, dated as of February 19, 2018. Read SEC document |
| January 13, 2023 Filed Jan 17, 2023 21:37 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | Tax withholdingCommon Stock, par value $0.005 | 319,231 | $9.36 | $2,988,002.16 |
DisclosureSEC source: 0001493152-23-001631 · ownership.xml · nonDerivative · entry 2 Karkus Ted William · CIK 0001457896 · Director · CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,352,087 F1 · kind: On January 13, 2023, the Reporting Person acquired net 280,769 shares of common stock upon the exercise of stock options to purchase 600,000 shares of common stock, less 319,231 shares of common stock withheld to cover the exercise price and applicable taxes. Read SEC document |
| January 13, 2023 Filed Jan 17, 2023 21:37 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | Exercise / conversionCommon Stock, par value $0.005 | 600,000 | $0.60 | $360,000.00 |
DisclosureSEC source: 0001493152-23-001631 · ownership.xml · nonDerivative · entry 1 Karkus Ted William · CIK 0001457896 · Director · CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,671,318 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On January 13, 2023, the Reporting Person acquired net 280,769 shares of common stock upon the exercise of stock options to purchase 600,000 shares of common stock, less 319,231 shares of common stock withheld to cover the exercise price and applicable taxes. Read SEC document |
| October 16, 2022 Filed Oct 18, 2022 13:34 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | Exercise / conversionOption (right to buy) · Derivative | 600,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001493152-22-028621 · ownership.xml · derivative · entry 4 Karkus Ted William · CIK 0001457896 · Director · CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,100,000 Underlying: Common Stock · 600,000 shares Expires 2023-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On October 16, 2022, the Reporting Person acquired net 282,709 shares of common stock upon the exercise of stock options to purchase 600,000 shares of common stock, less 317,291 shares of common stock withheld to cover the exercise price and applicable taxes. F2 · derivative.exercise_date: The option vested in 35 equal monthly installments of 63,888 shares on the 1st day of each month beginning on March 1, 2018 (the "Initial Vesting Date"), and one monthly installment of 63,920 shares on the 1st day of the 36th month following the Initial Vesting Date, as described in a stock option award agreement by and between the Issuer and the Reporting Person, dated as of February 19, 2018. Read SEC document |
| October 16, 2022 Filed Oct 18, 2022 13:34 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | Tax withholdingCommon Stock, par value $0.005 | 317,291 | $10.41 | $3,302,999.31 |
DisclosureSEC source: 0001493152-22-028621 · ownership.xml · nonDerivative · entry 2 Karkus Ted William · CIK 0001457896 · Director · CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,071,318 F1 · kind: On October 16, 2022, the Reporting Person acquired net 282,709 shares of common stock upon the exercise of stock options to purchase 600,000 shares of common stock, less 317,291 shares of common stock withheld to cover the exercise price and applicable taxes. Read SEC document |
| October 16, 2022 Filed Oct 18, 2022 13:34 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | Exercise / conversionCommon Stock, par value $0.005 | 600,000 | $0.60 | $360,000.00 |
DisclosureSEC source: 0001493152-22-028621 · ownership.xml · nonDerivative · entry 1 Karkus Ted William · CIK 0001457896 · Director · CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,388,609 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On October 16, 2022, the Reporting Person acquired net 282,709 shares of common stock upon the exercise of stock options to purchase 600,000 shares of common stock, less 317,291 shares of common stock withheld to cover the exercise price and applicable taxes. Read SEC document |
| August 10, 2022 Filed Aug 11, 2022 01:23 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | Exercise / conversionOption (right to buy) · Derivative | 600,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001493152-22-021940 · ownership.xml · derivative · entry 4 Karkus Ted William · CIK 0001457896 · Director · CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,700,000 Underlying: Common Stock · 600,000 shares Expires 2023-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On August 10, 2022, the Reporting Person acquired net 283,395 shares of common stock upon the exercise of stock options to purchase 600,000 shares of common stock, less 316,605 shares of common stock withheld to cover the exercise price and applicable taxes. F2 · derivative.exercise_date: The option vested in 35 equal monthly installments of 63,888 shares on the 1st day of each month beginning on March 1, 2018 (the "Initial Vesting Date"), and one monthly installment of 63,920 shares on the 1st day of the 36th month following the Initial Vesting Date, as described in a stock option award agreement by and between the Issuer and the Reporting Person, dated as of February 19, 2018. Read SEC document |
| August 10, 2022 Filed Aug 11, 2022 01:23 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | Tax withholdingCommon Stock, par value $0.005 | 316,605 | $10.84 | $3,431,998.20 |
DisclosureSEC source: 0001493152-22-021940 · ownership.xml · nonDerivative · entry 2 Karkus Ted William · CIK 0001457896 · Director · CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,788,609 F1 · kind: On August 10, 2022, the Reporting Person acquired net 283,395 shares of common stock upon the exercise of stock options to purchase 600,000 shares of common stock, less 316,605 shares of common stock withheld to cover the exercise price and applicable taxes. Read SEC document |
| August 10, 2022 Filed Aug 11, 2022 01:23 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | Exercise / conversionCommon Stock, par value $0.005 | 600,000 | $0.60 | $360,000.00 |
DisclosureSEC source: 0001493152-22-021940 · ownership.xml · nonDerivative · entry 1 Karkus Ted William · CIK 0001457896 · Director · CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,105,214 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On August 10, 2022, the Reporting Person acquired net 283,395 shares of common stock upon the exercise of stock options to purchase 600,000 shares of common stock, less 316,605 shares of common stock withheld to cover the exercise price and applicable taxes. Read SEC document |
| May 23, 2022 Filed May 25, 2022 21:20 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | Exercise / conversionOption (right to buy) · Derivative | 450,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001493152-22-015068 · ownership.xml · derivative · entry 4 Karkus Ted William · CIK 0001457896 · Director · CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 450,000 shares Expires 2024-04-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On May 23, 2022, the Reporting Person acquired net 171,743 shares of common stock upon the exercise of stock options to purchase 450,000 shares of common stock, less 278,257 shares of common stock withheld to cover the exercise price and applicable taxes. F2 · derivative.exercise_date: The option vested in four equal annual installments beginning April 26, 2018, as detailed in a stock option award agreement by and between the Issuer and the Reporting Person, dated as of April 27, 2017. Read SEC document |
| May 23, 2022 Filed May 25, 2022 21:20 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | Tax withholdingCommon Stock, par value $0.005 | 278,257 | $8.47 | $2,356,836.79 |
DisclosureSEC source: 0001493152-22-015068 · ownership.xml · nonDerivative · entry 2 Karkus Ted William · CIK 0001457896 · Director · CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,505,214 F1 · kind: On May 23, 2022, the Reporting Person acquired net 171,743 shares of common stock upon the exercise of stock options to purchase 450,000 shares of common stock, less 278,257 shares of common stock withheld to cover the exercise price and applicable taxes. Read SEC document |
| May 23, 2022 Filed May 25, 2022 21:20 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | Exercise / conversionCommon Stock, par value $0.005 | 450,000 | $2.00 | $900,000.00 |
DisclosureSEC source: 0001493152-22-015068 · ownership.xml · nonDerivative · entry 1 Karkus Ted William · CIK 0001457896 · Director · CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,783,471 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On May 23, 2022, the Reporting Person acquired net 171,743 shares of common stock upon the exercise of stock options to purchase 450,000 shares of common stock, less 278,257 shares of common stock withheld to cover the exercise price and applicable taxes. Read SEC document |
| June 03, 2021 Filed Jun 10, 2021 20:01 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | PurchaseCommon Stock, par value $0.005 | 33,943 | $5.07 | $171,921.30 |
DisclosureSEC source: 0001493152-21-014015 · ownership.xml · nonDerivative · entry 1 Karkus Ted William · CIK 0001457896 · Director · CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,333,471 F1 · shares: The transaction reported herein was an inadvertent purchase of Issuer common stock pursuant to an automatic broker-administered dividend reinvestment program. The dividend reinvestment feature of the reporting person's brokerage account has since been removed. Read SEC document |
| May 07, 2021 Filed May 10, 2021 21:30 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | GiftCommon Stock, par value $0.005 | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-010909 · ownership.xml · nonDerivative · entry 2 Karkus Ted William · CIK 0001457896 · Director · CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Son Disclosed balance after: 100,000 F1 · shares: Includes 60,000 shares that the Reporting Person gifted to his older son, who does not share the Reporting Person's household, and 60,000 shares that the Reporting Person gifted to his younger son, who does share the Reporting Person's household. Read SEC document |
| May 07, 2021 Filed May 10, 2021 21:30 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | GiftCommon Stock, par value $0.005 | 120,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-010909 · ownership.xml · nonDerivative · entry 1 Karkus Ted William · CIK 0001457896 · Director · CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,299,528 F1 · shares: Includes 60,000 shares that the Reporting Person gifted to his older son, who does not share the Reporting Person's household, and 60,000 shares that the Reporting Person gifted to his younger son, who does share the Reporting Person's household. Read SEC document |
| August 13, 2020 Filed Aug 17, 2020 20:30 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | SaleCommon Stock, par value $0.005 | 50,000 | $2.75 | $137,500.00 |
DisclosureSEC source: 0001493152-20-016100 · ownership.xml · nonDerivative · entry 1 Karkus Ted William · CIK 0001457896 · Director · CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,419,528 F1 · shares: These shares were sold in a private transaction to Louis Gleckel, a director of the Issuer, pursuant to the terms of a Stock Purchase Agreement. Read SEC document |
| July 09, 2020 Filed Jul 14, 2020 00:39 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | GiftCommon Stock, par value $0.005 | 28,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-013210 · ownership.xml · nonDerivative · entry 3 Karkus Ted William · CIK 0001457896 · Director · CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Son Disclosed balance after: 40,000 F2 · balance_after: Includes an additional 11,400 shares held by the Reporting Person's son that were previously included in the Reporting Person's direct holdings. Read SEC document |
| July 09, 2020 Filed Jul 14, 2020 00:39 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | GiftCommon Stock, par value $0.005 | 25,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-013210 · ownership.xml · nonDerivative · entry 2 Karkus Ted William · CIK 0001457896 · Director · CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Son Disclosed balance after: 40,000 F1 · balance_after: Includes an additional 14,450 shares held by the Reporting Person's son that were previously included in the Reporting Person's direct holdings. Read SEC document |
| July 09, 2020 Filed Jul 14, 2020 00:39 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | GiftCommon Stock, par value $0.005 | 54,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-013210 · ownership.xml · nonDerivative · entry 1 Karkus Ted William · CIK 0001457896 · Director · CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,469,528 Read SEC document |
| March 26, 2020 Filed Mar 27, 2020 23:15 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | SaleCommon Stock, par value $0.005 | 100,000 | $1.75 | $175,000.00 |
DisclosureSEC source: 0001493152-20-004961 · ownership.xml · nonDerivative · entry 1 Karkus Ted William · CIK 0001457896 · Director · CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,549,528 Read SEC document |
| May 15, 2018 Filed May 17, 2018 16:40 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001493152-18-007358 · form4.xml · derivative · entry 6 Karkus Ted William · CIK 0001457896 · Director · CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 150,000 shares Expires 2024-04-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: There employee stock options vested in an annual installment of 150,000 shares on April 26, 2018. Read SEC document |
| May 15, 2018 Filed May 17, 2018 16:40 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001493152-18-007358 · form4.xml · derivative · entry 5 Karkus Ted William · CIK 0001457896 · Director · CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2019-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These employee stock options vested in annual installments of 50,000 and 50,000 shares on December 19, 2014 and 2015, respectively. Read SEC document |
| May 15, 2018 Filed May 17, 2018 16:40 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | Tax withholdingCommon Stock, par value $0.005 | 55,046 | $5.45 | $300,000.70 |
DisclosureSEC source: 0001493152-18-007358 · form4.xml · nonDerivative · entry 4 Karkus Ted William · CIK 0001457896 · Director · CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,649,528 Read SEC document |
| May 15, 2018 Filed May 17, 2018 16:40 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | Exercise / conversionCommon Stock, par value $0.005 | 150,000 | $2.00 | $300,000.00 |
DisclosureSEC source: 0001493152-18-007358 · form4.xml · nonDerivative · entry 3 Karkus Ted William · CIK 0001457896 · Director · CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,704,574 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2018 Filed May 17, 2018 16:40 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | Tax withholdingCommon Stock, par value $0.005 | 30,275 | $5.45 | $164,998.75 |
DisclosureSEC source: 0001493152-18-007358 · form4.xml · nonDerivative · entry 2 Karkus Ted William · CIK 0001457896 · Director · CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,554,574 Read SEC document |
| May 15, 2018 Filed May 17, 2018 16:40 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | Exercise / conversionCommon Stock, par value $0.005 | 100,000 | $1.65 | $165,000.00 |
DisclosureSEC source: 0001493152-18-007358 · form4.xml · nonDerivative · entry 1 Karkus Ted William · CIK 0001457896 · Director · CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,584,849 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2018 Filed Feb 26, 2018 21:23 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | GrantOption (right to buy) · Derivative | 2,300,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001493152-18-002597 · form4.xml · derivative · entry 1 Karkus Ted William · CIK 0001457896 · Director · CEO & Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,300,000 Underlying: Common Stock · 2,300,000 shares Expires 2023-02-22 F1 · derivative.exercise_date: The transaction reported in this row involves a grant by the Issuer to the Reporting Person of options to purchase 2,300,000 shares of the Issuer's common stock that will vest and be exercisable in 35 equal monthly installments of 63,888 shares on the 1st day of each month beginning on March 1, 2018 (the "Initial Vesting Date"), and one monthly installment of 63,920 shares on the 1st day of the 36th month following the Initial Vesting Date, subject to Mr. Karkus' continued employment with the Company, and subject to accelerated vesting in the event Mr. Karkus' employment is terminated for any reason other than by the Company for cause or by Mr. Karkus without good reason. The stock option may not be exercised unless and until the requisite stockholder approval is attained. Read SEC document |
| December 21, 2017 Filed Dec 26, 2017 20:02 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | SaleCommon Stock, par value $0.005 | 424,789 | $2.30 | $977,014.70 |
DisclosureSEC source: 0001493152-17-015051 · form4.xml · nonDerivative · entry 1 Karkus Ted William · CIK 0001457896 · Director · CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,484,849 F1 · balance_after: These shares were sold to the Issuer through the tender offer by the Issuer for 1,700,000 shares of its common stock. Read SEC document |
| December 14, 2017 Filed Dec 18, 2017 21:00 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 600,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001493152-17-014721 · form4.xml · derivative · entry 2 Karkus Ted William · CIK 0001457896 · Director · CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 600,000 shares Expires 2017-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These employee stock options vested in annual installments of 100,000, 100,000, 100,000 and 300,000 shares on December 14, 2011, 2012, 2013 and 2014, respectively. Read SEC document |
| December 14, 2017 Filed Dec 18, 2017 21:00 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | Exercise / conversionCommon Stock, par value $0.005 | 600,000 | $1.00 | $600,000.00 |
DisclosureSEC source: 0001493152-17-014721 · form4.xml · nonDerivative · entry 1 Karkus Ted William · CIK 0001457896 · Director · CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,909,638 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 29, 2017 Filed Oct 2, 2017 16:53 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | SaleCommon Stock, par value $0.005 | 364,950 | $2.30 | $839,385.00 |
DisclosureSEC source: 0001493152-17-011126 · form4.xml · nonDerivative · entry 1 Karkus Ted William · CIK 0001457896 · Director · CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,309,638 F1 · shares: These shares were sold to the Issuer through the tender offer by the Issuer for 4,000,000 shares of its common stock. Read SEC document |
| April 27, 2017 Filed Apr 28, 2017 17:18 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | GrantOption (right to buy) · Derivative | 600,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001493152-17-004512 · form4.xml · derivative · entry 1 Karkus Ted William · CIK 0001457896 · Director · CEO & Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2024-04-27 F1 · derivative.exercise_date: The transaction reported in this row involves a grant by the Issuer to the Reporting Person of options to purchase the Issuer's common stock that will vest in four equal annual installments beginning April 26, 2018, as detailed in a stock option award agreement by and between the Issuer and the Reporting Person, dated as of April 27, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.